Expert Opinion on Drug Safety

Article	Citations
Novel insights into post-marketing AEs associated with bempedoic acid: a comprehensive analysis utilizing the FAERS database	101
Drug-induced hepatitis B virus reactivation: insights from FAERS database analysis	76
Adverse event profiles of drug-induced decreased libido: an assessment of the US food and drug administration Adverse Event Reporting System	71
Resistance to hedgehog inhibitors in basal cell carcinoma: strategies to adopt	63
Adverse events in patients with cardiovascular disease taking proton pump inhibitors	54
An update on the cognitive safety of antimuscarinics in the treatment of overactive bladder	44
Exploration and evaluation of adverse event signals of droxidopa based on the FAERS database	43
Safety profile of isocitrate dehydrogenase inhibitors in cancer therapy: a pharmacovigilance study of the FDA Adverse Event Reporting System	42
The safety of phthalate-containing medications used during pregnancy	42
A real-world pharmacovigilance study of QT interval prolongation and Torsades de Pointes associated with CDK4/6 inhibitors in breast cancer patients: findings from the FDA adverse event reporting syst	42
Exploration of cardiac adverse events associated with relugolix and degarelix: a multi-center pharmacovigilance study based on the FAERS database	37
Infectious events in patients with alopecia areata treated with JAK inhibitors: low burden and minimal impact on persistence in treatment	33
Comparison of adverse events of poly adenosine diphosphate ribose polymerase inhibitors in patients with ovarian cancer using the United States Food and Drug Administration Adverse Event Reporting Sys	31
Assessment of adverse events related to anti-interleukin-6 receptor monoclonal antibodies using the FDA adverse event reporting system: a real-world pharmacovigilance study	28
Mechanism and clinical utility of abatacept in the treatment of rheumatoid arthritis	27
Assessment of adverse events of the novel antiepileptic drug lamotrigine: a real-world pharmacovigilance study based on FAERS	25
The role of artificial intelligence in pharmacovigilance for rare diseases	25
An updated safety review of Hidradenitis Suppurativa treatment options	24
Safety assessment of brexanolone in the FAERS database: real adverse event analysis and discussion of side effects	22
Long-term safety of ketamine and esketamine in treatment of depression	22
The safety profile of azithromycin in pediatrics: a pharmacovigilance disproportionality analysis	21
Underuse of GLP-1 receptor agonists in the management of type 2 diabetes despite a favorable benefit-safety profile	21
Diarrhea-predominant irritable bowel syndrome treatment options eluxadoline, rifaximin, and alosetron: analysis of the FDA adverse event reporting system (FAERS) database	20
The effectiveness and safety of aripiprazole, bromocriptine, and cabergoline in the treatment of hyperprolactinemia: a systematic review and network meta-analysis	19
Risk of acute kidney injury in patients receiving vancomycin and concomitant piperacillin-tazobactam or carbapenem: a multicenter, retrospective cohort study	19

Pharmacovigilance approaches to study rare and very rare side-effects: the example of clozapine-related DiHS/DRESS syndrome	19
Newly identified adverse events of enzalutamide using the food and drug administration adverse event reporting system	18
Proton pump inhibitors and increased reporting odds of renal neoplasms: FAERS-based adverse event data mining and analysis	18
The Impact of Medication Regimen Complexity Score on Multi-Organ Dysfunction and Clinical Outcomes in Critically Ill Patients: A Cohort Study	17
A safety review of approved oral agents for treating type 2 diabetes and associated diseases in pregnant patients	17
Safety evaluation of the DTaP5-IPV-Hib-HepB vaccine: a review	17
Safety concerns associated with BACE1 inhibitors – past, present, and future	17
Safety and efficacy of anti-SARS-CoV-2 monoclonal antibodies in pregnancy	16
Correction	16
Unveiling the hidden ocular risks of isotretinoin: a comprehensive FAERS-Based analysis	16
Does the use of generative AI chatbots by patients introduce risk of adverse drug events?	16
Safety of current antiviral drugs for chronic hepatitis B	15
Disease-specific ADRs of TNF-α inhibitors as reported by patients with inflammatory rheumatic diseases: a registry-based prospective multicenter cohort study	15
Comparative analysis of CDKI-related adverse events in older patients: a real-world data from the FDA adverse event reporting system database	15
Comparative disproportionality analysis of adverse events associated with combined therapy versus monotherapy of abiraterone and olaparib for prostate cancer: a pharmacovigilance study using the FAERS	15
Post-marketing safety concerns with palbociclib: a disproportionality analysis of the FDA adverse event reporting system	15
Sodium-glucose cotransporter-2 inhibitors and cardiovascular safety profile: a pharmacovigilance analysis of the US food and drug administration adverse event reporting system	15
First-time adverse drug reactions, survival analysis, and the share of adverse drug reactions in treatment discontinuation in real-world rheumatoid arthritis patients: a comparison of first-time treat	15
Long-term safety and effectiveness of vonoprazan for prevention of gastric and duodenal ulcer recurrence in patients on nonsteroidal anti-inflammatory drugs in Japan: a 12-month post-marketing surveil	15
Update of safety profile of levonorgestrel: a disproportionality analysis based on FAERS from 2004 to 2023	14
A real-world disproportionality analysis of baloxavir marboxil: post-marketing pharmacovigilance data	14
Post-marketing safety evaluation of zanubrutinib: a real-world pharmacovigilance analysis based on the FAERS database	14
Corticosteroids for the treatment of Duchenne muscular dystrophy: a safety review	14
Tirzepatide and glucagon-like peptide-1 receptor agonists: safety always comes first!	14
Safety and effectiveness of empagliflozin in Japanese patients with type 2 diabetes: final results of a 3-year post-marketing surveillance study	14
Gastrointestinal adverse events associated with immune checkpoint inhibitors: a pharmacovigilance analysis of the EudraVigilance and VigiAccess databases	13
Disproportionality analysis of the safety profile of rufinamide in the real world: an evaluation of the FDA Adverse Event Reporting System database	12
SSRI withdrawal syndrome in children and adolescents: a narrative literature review	12
Cardiovascular adverse events in patients with HER2-positive breast cancer treated with trastuzumab-drug conjugates : a Bayesian disproportional real world study for signal detection leveraging the FD	12
Hallucinations and delusions associated with Parkinson’s disease psychosis: safety of current treatments and future directions	12
Data mining for signal detection of adverse events for taxanes based on the food and drug administration adverse drug events reporting system database	12
Safety of intranasal corticosteroids for allergic rhinitis in children	12
Antibody-drug conjugates-related interstitial lung diseases: data mining of the FAERS database	11
Drug-induced erectile dysfunction: a real-world pharmacovigilance study using the FDA adverse event reporting system database	11
Assessment of adverse events of tasimelteon: a real-world pharmacovigilance study based on FAERS	11
Exploration of the clinical characteristics and potential mechanisms of liver injury induced by proton pump inhibitors	11
Safety considerations for drugs newly approved for treating acute myeloid leukemia	11
Differences in safety profiles of anti-herpesvirus medications: a real-world pharmacovigilance study based on the FAERS database	11
Anticoagulant-associated calciphylaxis: analysis of USFDA adverse event report system and clinical feature analysis of reported cases	11
Drug-induced myocarditis: a real-world pharmacovigilance study using the FDA adverse event reporting system database	11
A safety evaluation of sucroferric oxyhydroxide for the treatment of hyperphosphatemia	11
Development and validation of a nomogram to predict the risk of potentially inappropriate medication use in older lung cancer outpatients with multimorbidity	11
Influence factors of metronidazole-related CNS disorders: an analysis of the Japan adverse drug event report and FDA adverse event reporting system	11
Data pharmacovigilance analysis of medroxyprogesterone-related adverse events in the FDA adverse event reporting system	11
Adverse events associated with acute pancreatitis caused by immune checkpoint inhibitors: a pharmacovigilance analysis of the FDA adverse event reporting system (FAERS) database	11
Long-term safety of lanthanum carbonate in the real word: a 19-year disproportionality analysis from the FDA Adverse Event Reporting System	10
A real-world pharmacovigilance study of axitinib: data mining of the public version of FDA adverse event reporting system	10
Safety considerations for prescribing SSRI antidepressants to patients at increased cardiovascular risk	10
How do safety warnings on medicines affect prescribing?	10
The use of hydroxyurea in the real life of MIOT network: an observational study	10

Current safety concerns about the use of antiseizure medications in pregnancy	10
Association between dual orexin receptor antagonists (DORAs) and suicidality: reports to the United States Food and Drug Administration Adverse Event Reporting System (FAERS)	10
Drug safety evaluation of ixekizumab for psoriasis: a review of the current knowledge	10
Vancomycin and linezolid: severe cutaneous adverse reactions to drugs	10
Long-term safety profile and secondary effectiveness of canakinumab in pediatric rheumatic diseases: a single-center experience	10
Treatment free remission (TFR) after second-generation tyrosine kinase inhibitors (2G-TKIs) treatment in chronic myeloid leukemia (CML): from feasibility to safety	10
Comparative effectiveness and safety of drug therapy for chronic urticaria: a network meta-analysis and risk-benefit assessment	10
Ocular toxicities associated with antibody drug conjugates and immunotherapy in oncology: clinical presentation, pathogenesis, and management strategies	9
Adverse events associated with inclisiran: a real-world disproportionality analysis based on the FAERS database	9
Safety of marketed biosimilar monoclonal antibody cancer treatments in the US: a disproportionality analysis using the food and drug administration adverse event reporting system (FAERS) database	9
Updated insights on levetiracetam-associated severe cutaneous adverse reactions: a real-world pharmacovigilance analysis	9
Drug-induced hyperacusis: a disproportionality analysis of the FAERS database	9
Congenital anomalies associated with the use of cardiovascular drugs during pregnancy: a large-scale data analysis from the FAERS database	9
Adverse events of direct factor Xa inhibitors: a disproportionality analysis of the FAERS database	9
Adverse events associated with aromatase inhibitors: an analysis of real-world datasets and drug-gene interaction network	9
Adverse event signal analysis of type Ib MET tyrosine kinase inhibitors based on food and drug administration adverse event reporting system	9
Will the future of pharmacovigilance be more automated?	9
Hemorrhage profile associated with immune checkpoint inhibitors: a systematic review and a real-world study based on the FAERS database	9
Adverse event profile of ocular injury associated with JAK inhibitors in patients with rheumatoid arthritis: a disproportionality analysis	9
Comparing musculoskeletal and connective tissue disorder risks of teriparatide and abaloparatide in osteoporosis: an analysis based on FDA adverse event reporting system (FAERS)	8
Detection of risk signals for ustekinumab in the real world using the FDA Adverse Event Reporting System (FAERS)	8
Biosimilars and immunogenicity: a matter of concern?	8
Treating psychosis in people with Parkinson’s disease	8
Skin cancer associated with calcineurin inhibitors treatment: analysis of FAERS database	8
Analysis of the relationship between histamine H1 receptor antagonists and broad dementia events using the FAERS, JADER, and CVAR databases	8
A real‑world pharmacovigilance study of FDA adverse event reporting system events for daratumumab	8
Generic pharmaceuticals, regulatory aspects, bioequivalence investigation, and perception	8
Potential drugs for reducing the occurrence of immune checkpoint inhibitor-induced interstitial lung disease: an exploratory study using the JADER and FAERS databases	8
Impact of preoperative pharmaceutical care consultation on medication errors in surgical patients: a comprehensive analysis	8
Safety evaluation of ILaris: a real-world analysis of adverse events based on the FAERS database	8
Safety of medications for hereditary angioedema during pregnancy and lactation	7
Cardiovascular toxicities of selective ret-specific tyrosine kinase inhibitors: a pharmacovigilance study based on the United States Food and Drug Administration Adverse Event Reporting System databas	7
Reporting of tumor lysis syndrome with targeted therapy for hepatic cancer in the FDA adverse events reporting system	7
Investigating bleeding adverse events associated with BTK inhibitors in the food and drug administration adverse event reporting system (FAERS)	7
A review on side effect management of second-generation antipsychotics to treat schizophrenia: a drug safety perspective	7
Hepatobiliary disorders and Direct-Acting Antiviral (DAA) therapies: real-world evidence and insights from the EudraVigilance database	7
Contributory factors and patient harm including deaths associated direct acting oral anticoagulants (DOACs) medication incidents: evaluation of real world data reported to the National Reporting and L	7
The efficacy and safety of Capivasertib (AZD5363) in the treatment of patients with solid tumor: a systematic review and meta-analysis of randomized clinical trials	7
Clozapine may consistently protect from suicidal behaviors while other antipsychotics may lack a specific protective effect: a comprehensive VigiBase study interpreted in the context of the prior lite	7
Drug-induced dementia: a pharmacovigilance analysis of the FAERS database	7
The role of co-morbidities in the development of an AEFI after COVID-19 vaccination in a large prospective cohort with patient-reported outcomes in the Netherlands	7
Ocular adverse events of cenegermin used in neurotrophic keratopathy: an analysis of the FDA adverse event reporting system database	7
Effects of adding adjuvants to propofol on the post-anesthesia cognitive function in patients undergoing gastroscopy/colonoscopy: a systematic review and meta-analysis	7
Nobel Prize for immune checkpoint inhibitors, understanding the immunological switching between immunosuppression and autoimmunity	7
An update on the safety of ixazomib for the treatment of multiple myeloma	7
Liver toxicity in oncology trials and beyond: a simplified concept for management of hepatocellular drug-induced liver injury in patients with abnormal baseline liver tests	7
Comparison of four criteria for potentially inappropriate medications in older patients with newly diagnosed non-small cell lung cancer	7
Risk factors analysis and construction of predictive models for acute kidney injury in overweight patients receiving vancomycin treatment	7
Completeness of pharmaceutical industry insulin adverse event reports from Africa and the Middle East	7
Safety profiles of tetracycline-class drugs: a pharmacovigilance analysis of the FAERS database	7
Real-world safety evaluation of brivaracetam: insights from the US FDA Adverse Event Reporting System	7
Safety evaluation of secukinumab in pediatric patients with plaque psoriasis	7
Seizures associated with antibiotics: a real-world disproportionality analysis of FAERS database	6
Study on analgesic-induced endocrine gland damage and its potential mechanisms	6
A new paradigm in adverse drug reaction reporting: consolidating the evidence for an intervention to improve reporting	6
Meeting report: an exploration into the scientific and regulatory aspects of pharmaceutical drug quality in the United States	6
Correction	6
Drug-induced nephrolithiasis: a real-world pharmacovigilance study of the FDA Adverse Event Reporting System	6
Safety issues of psilocybin and LSD as potential rapid acting antidepressants and potential challenges	6
Efficacy and safety of biologics and small molecules for psoriasis in pediatric and geriatric populations. Part I: focus on pediatric patients	6
Cognitive dysfunction following finasteride use: a disproportionality analysis of the global pharmacovigilance database	6
The impact of the COVID-19 pandemic on adverse events associated with ACEIs and ARBs: a real-world analysis using the FDA adverse event reporting system	6
Can the revival of serotonergic psychedelic drugs as treatments for mental disorders help to characterize their risks and benefits?	6
Oral isotretinoin for acne: a complete overview	6
Dupilumab in real-life settings: a review of adverse events and their pathogenesis	6
COVID-19 vaccine safety studies- the need for a third group for extended monitoring	6
Comparative evaluation of adverse drug reactions for tenofovir alafenamide and tenofovir disoproxil fumarate using the FAERS Database: a disproportionality analysis	6
Adverse events associated with inclisiran: a real-world pharmacovigilance study of FDA adverse event reporting system (FAERS)	6
Postmarketing safety of [ 177 Lu]Lu-PSMA-617 radioligand therapy for prostate cancer: a disproportionality analysis of the FDA adverse event reporting system	6
Signal mining and gender differences analysis of adverse events in NMIBC treatment with gemcitabine and BCG bladder instillation based on the FAERS database	6
Drug-induced Stevens-Johnson syndrome: a disproportionality analysis from the pharmacovigilance database of the World Health Organization	6
Opioid-related adverse drug events in surgical patients: risk factors and association with clinical outcomes	6
COMfort Eye Trial (COMET) results - a non-inferiority, randomized, investigator-masked, two-parallel group, phase III clinical trial, to evaluate the efficacy and safety of a preservative free formula	5
Safety of ramucirumab treatment in patients with advanced hepatocellular carcinoma and elevated alpha-fetoprotein	5
Barriers and facilitators for systematically registering adverse drug reactions in electronic health records: a qualitative study with Dutch healthcare professionals	5
Safety assessment of tafamidis: a real-world adverse event analysis from the FAERS database	5
Cardiovascular adverse events associated with EGFR and HER2 dual TKIs: a pharmacovigilance study based on the FAERS database	5
Pharmacovigilance insights into drug-induced cystitis: analysis of FDA data from 2004 to 2024	5
The safety of available pharmacotherapy for stroke prevention in atrial fibrillation	5
Incidence, clinical characteristics and related drugs analyzing of drug-induced movement disorders in 102914 inpatients: a retrospective real-world study	5

The safety and efficacy of sugammadex for reversing neuromuscular blockade in younger children and infants	5
Comparison of safety of acetaminophen and ibuprofen in minors: based on the FAERS database	5
Management of refractory checkpoint inhibitor-induced colitis	5
Post-marketing safety surveillance of Amivantamab: a real world study based on the FDA adverse event reporting system	5
Breast cancer treatment-related cardiovascular disturbances: advocacy for a watchful attitude in this never-ending story	5
Investigating the risk of deep vein thrombosis with JAK inhibitors: a disproportionality analysis using FDA Adverse Event Reporting System Database (FAERS)	5
The therapeutic potential of psilocybin: a systematic review	5
Ten years-experience of sunitinib in the treatment of advanced pan-NETs: an update on safety profile	5
Safety and tolerability of linagliptin in Asians with type 2 diabetes: a pooled analysis of 4457 patients from 21 randomized, double-blind, placebo-controlled clinical trials	5
A narrative review of the comparative safety of disease-modifying anti-rheumatic drugs used for the treatment of rheumatoid arthritis	5
Injection site reactions resulting from the use of biological therapy in the treatment of moderate-to-severe plaque psoriasis	5
Approved treatments for neovascular age-related macular degeneration: current safety and future directions	5
Post-marketing safety of panitumumab: a real-world pharmacovigilance study	5
Compared of efficacy and safety of high-dose donepezil vs standard-dose donepezil among elderly patients with Alzheimer’s disease: a systematic review and meta-analysis	5
Intraocular inflammation as a major adverse event of anti-vascular endothelial growth factor therapy for neovascular age-related macular degeneration: from clinical trials to real-world practice	5
Concomitant use of sodium-glucose co-transporter 2 inhibitors and metformin and the risk of osteomyelitis reporting: a disproportionality analysis based on FAERS database	5
Comment about the safety of intravenous voriconazole formulated with sulfobutylether beta-cyclodextrin	5
Immune checkpoint inhibitor related myositis: an observational, retrospective, pharmacovigilance study	5
The effect of patient sex on the efficacy and safety of anticancer immunotherapy	5
Assessment of safety profile of ivabradine in real-world scenario using FDA adverse event reporting system database	5
Pre- and post-operative safety considerations for patients undergoing percutaneous nephrolithotomy	5
Characteristics of adverse drug reactions induced by flutamide and bicalutamide: a real-world pharmacovigilance study using FAERS	5
A retrospective study to evaluate Hy’s Law, DrILTox ALF score, Robles-Diaz model, and a new logistic regression model for predicting acute liver failure in Chinese patients with drug-induced liver inj	5
Reviewing the evidence surrounding preservative-free tafluprost/timolol fixed-dose combination therapy in open-angle glaucoma and ocular hypertension management: a focus on efficacy, safety, and toler	5
Potential side effects of currently available pharmacotherapies in male lower urinary tract symptoms suggestive of benign prostatic hyperplasia	5
Analyzing the patterns of adverse drug reactions due to anti-infectives from large-scale nationwide database in Thailand	5
A real-world pharmacovigilance study of blinatumomab based on the FDA adverse event reporting system	5
A comparative analysis of the safety profiles between inclisiran and other PCSK9 inhibitors from real-world evidence – what have we learned recently?	5
Priapism associated with anti-seizure medications: a pharmacovigilance study and a review of published cases	4
Central serous chorioretinopathy secondary to drugs: a real-world pharmacovigilance study of the FDA adverse event reporting system (FAERS)	4
Influence of prior treatment protocol on intravitreal dexamethasone implant behavior in patients with diabetic macular edema in real-world practice	4
Dalbavancin in the treatment of acute bacterial skin and skin structure and other infections: a safety evaluation	4
An overview of methodological flaws of real-world studies investigating drug safety in the post-marketing setting	4
Actual drug-related harms in residential aged care facilities: a narrative review	4
Suspected statin-related adverse drug reactions: analysis of spontaneous reports in Hubei Province, China (2014–2022)	4
Evaluating the Impact of Black Box Warning Updates on the Reporting of Drug-Related Adverse Events: a Cross Sectional Study of the FAERS Database	4
Appropriateness of psychopharmacological therapies to psychiatric diagnoses in persons with autism spectrum disorder with or without intellectual disabilities: a cross-sectional analytic study	4
Adverse event profile of setmelanotide in obesity: an integrated assessment and systematic review using disproportionality analysis, case reports and meta-analysis	4
Risk factors, prevention and treatment of weight gain associated with the use of antidepressants and antipsychotics: a state-of-the-art clinical review	4
Venous thromboembolism risk with Janus kinase inhibitors: Is it a class wide effect?	4
Incidence and risk of treatment-related fatal adverse events in cancer patients treated with antibody conjugated drugs: a systematic review and meta-analysis of randomized controlled trials	4
Correction	4
Examining the safety of belimumab, especially in children: an analysis of real-world pharmacovigilance data from the US FDA adverse event reporting system (FAERS) database	4
Neural dysfunction, inflammatory disorder, and metabolic interference feature in amantadine-related adverse drug events: a perspective from FAERS and network toxicology	4
Serotonin 5-HT 2B receptor agonism and valvular heart disease: implications for the development of psilocybin and related agents	4
Clozapine-treated patients and myocardial infarction in adults: a pharmacovigilance study in VigiBase interpreted in the context of the literature	4
Efficacy and safety of sonidegib for the management of basal cell carcinoma: a drug safety evaluation	4
Mining and analysis of adverse events associated with aducanumab: a real-world study using FDA Adverse Event Reporting System database	4
Risk of serious skin and subcutaneous tissue disorders for nimesulide among the pediatric population: a jeopardy identified through the analysis of global individual case safety reports	4
Post-marketing safety monitoring of tirzepatide: a pharmacovigilance study based on the FAERS database	4
Infectious complications associated with immune and targeted anti-cancer therapies: a retrospective study of the FDA adverse events reporting system (FAERS)	4
Major adverse events associated with lipid reduction in inclisiran: a pharmacovigilance research of the FAERS database	4
Systemic quinolones and risk of retinal detachment I: analysis of data from the US FDA adverse event reporting system	4
New exploration of signal detection of Regional Risks from the perspective of data mining: a pharmacovigilance analysis based on spontaneous reporting data in Zhenjiang, China	4
A real-world pharmacovigilance case/non-case study of FDA adverse event reporting system events for mannitol	4
Safety profile of lasmiditan in patients with migraine in an Asian population	4
Cyclin-dependent kinase 4/6 inhibitor-associated pulmonary toxicity: a disproportionality analysis from 2015 to 2023 based on the FAERS database	4
Identification of novel signal of Raynaud’s phenomenon with Calcitonin Gene-Related Peptide(CGRP) antagonists using data mining algorithms and network pharmacological approaches	4
PD-1/PD-L1 inhibitors-associated cardiac adverse events: a retrospective and real-world study based on the FDA Adverse Event Reporting System (FAERS)	4
An umbrella review of systematic reviews on contributory factors to medication errors in health-care settings	4
Efficacy and safety of racemic ketamine and esketamine for depression: a systematic review and meta-analysis	4
Use of medroxyprogesterone acetate and risk of meningiomas: a comparative safety study	4
Comparative safety review of antithrombotic treatment options for patients with atrial fibrillation undergoing percutaneous coronary intervention	4
Assessment of Riociguat-related adverse events: a disproportionality analysis utilizing the FDA adverse event reporting system database	4
Adverse effects associated with antipsychotic use in older adults	4
Is the psychedelic experience an essential aspect of the therapeutic effect of serotonergic psychedelics? Conceptual, discovery, development and implementation implications for psilocybin and related	4
Improving the risk-to-benefit ratio of inhaled corticosteroids through delivery and dose: current progress and future directions	4
Quality of life in ovarian cancer patients treated with bevacizumab: a meta-analysis	4
Evaluation of the safety and efficacy of biosimilar recombinant growth hormone in children with growth hormone deficiency: non-inferiority, randomized, parallel, multicentric and Phase III trial	4
Safety analysis of fluoroquinolone drugs in elderly patients over 65 based on FAERS	4
Constipation-predominant irritable bowel syndrome treatment options Linaclotide, Lubiprostone, Plecanatide, and Tenapanor: analysis of the FDA Adverse Event Reporting System (FAERS) database	4
Pulmonary adverse events associated with amiodarone: a real-world pharmacovigilance study based on the FDA adverse event reporting system	4
Post-marketing safety assessment of constipation drugs: a real-world pharmacovigilance study based on FAERS database	4
Anaphylactic risk associated with iodinated and gadolinium-based contrast media	4
Hematopoietic adverse events associated with PARP inhibitors: A FAERS database study	4
Safety of PARP inhibitors as maintenance therapy in ovarian cancer	4